GGrantIndex
← Leaderboards

John H Connor

Wake Forest University Health Sciences

Google Scholar ↗PubMed ↗ORCID ↗
$10,610,959
Attributed
$15,604,438
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY2006–25
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,604,438 · 11

By mechanism

R01$13,424,192 · 3
R21$1,358,105 · 3
U54$403,705 · 2
K22$270,000 · 1
R03$81,725 · 1
F32$66,711 · 1

Top collaborators

Others in their field

Top investigators on “Virus”

Research focus

VirusInfectionViralCellsLeadDisease OutbreaksPathogenAnimal ModelReportingCollaborationsPharmaceutical PreparationsRna VirusesIn VivoVaccinesResponseVirus ReplicationProductionGeneticDoseSmall MoleculeInfectious AgentBaseTechnologyProteins

Grant awards (29)

Advancement of a poxvirus antiviral$2,607,328
R01 · FY2025 · AI · contact PI
Advancement of poxvirus inhibitor$745,122
R01 · FY2024 · AI · contact PI
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$705,488
R01 · FY2024 · HL · contact PI
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$732,287
R01 · FY2023 · HL · contact PI
Advancement of poxvirus inhibitor$656,410
R01 · FY2023 · AI · contact PI
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$665,322
R01 · FY2022 · HL · contact PI
Advancement of poxvirus inhibitor$593,447
R01 · FY2022 · AI · contact PI
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip$721,633
R01 · FY2021 · HL · contact PI
Advancement of poxvirus inhibitor$590,147
R01 · FY2021 · AI · contact PI
Advancement of poxvirus inhibitor$575,718
R01 · FY2020 · AI · contact PI
Genetic probing of residues involved in ebolavirus glycoprotein entry$206,250
R21 · FY2019 · AI · contact PI
Genetic probing of residues involved in ebolavirus glycoprotein entry$247,500
R21 · FY2018 · AI · contact PI
Assessment of infection route and vulnerability of neural precursor classes to Zika virus$205,729
R21 · FY2017 · NS
Role for polyamines in Ebola Virus Replication$205,625
R21 · FY2017 · AI · contact PI
Assessment of infection route and vulnerability of neural precursor classes to Zika virus$246,750
R21 · FY2016 · NS
Role for polyamines in Ebola Virus Replication$246,251
R21 · FY2016 · AI · contact PI
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve$708,299
R01 · FY2015 · AI · contact PI
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve$872,644
R01 · FY2014 · AI · contact PI
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve$836,193
R01 · FY2013 · AI · contact PI
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve$991,807
R01 · FY2012 · AI · contact PI
Stage-Specific Inhibitors of Orthopoxviruses$40,913
R03 · FY2012 · MH · contact PI
Development of Near Real-Time, Multiplexed Diagnostics for Viral Hemorrhagic Feve$1,422,347
R01 · FY2011 · AI · contact PI
Stage-Specific Inhibitors of Orthopoxviruses$40,812
R03 · FY2011 · MH · contact PI
New Ops-Proof of Concept Studies on a Class of Broad Spectrum Antiviral Compounds$170,848
U54 · FY2009 · AI · contact PI
New Ops: Proof of concept studies on a class of broad spectrum antiviral compound$232,857
U54 · FY2008 · AI · contact PI
Control of elF4F complex by Vesicular Stomatitis Virus$108,000
K22 · FY2007 · AI · contact PI
Control of elF4F complex by Vesicular Stomatitis Virus$162,000
K22 · FY2006 · AI · contact PI
Protein synthesis control by vesicular stomatits virus$20,519
F32 · FY2004 · AI
Protein synthesis control by vesicular stomatits virus$46,192
F32 · FY2003 · AI